These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 24620920)
21. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
22. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals. Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879 [TBL] [Abstract][Full Text] [Related]
23. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. Wang LC; Chen EQ; Cao J; Liu L; Wang JR; Lei BJ; Tang H J Viral Hepat; 2010 Mar; 17(3):178-84. PubMed ID: 19656287 [TBL] [Abstract][Full Text] [Related]
25. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL; N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735 [TBL] [Abstract][Full Text] [Related]
26. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742 [TBL] [Abstract][Full Text] [Related]
27. [Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study]. Zhao H; Li J; Zhang YX; Chen XY; Wang L; Tang XP; Lei CL; Si CW Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):282-4. PubMed ID: 17971947 [TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Jonas MM; Kelly D; Pollack H; Mizerski J; Sorbel J; Frederick D; Mondou E; Rousseau F; Sokal E Hepatology; 2008 Jun; 47(6):1863-71. PubMed ID: 18433023 [TBL] [Abstract][Full Text] [Related]
29. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL; Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524 [TBL] [Abstract][Full Text] [Related]
31. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288 [TBL] [Abstract][Full Text] [Related]
33. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. Hui CK; Zhang HY; Bowden S; Locarnini S; Luk JM; Leung KW; Yueng YH; Wong A; Rousseau F; Yuen KY; Naoumov NN; Lau GK J Hepatol; 2008 May; 48(5):714-20. PubMed ID: 18207280 [TBL] [Abstract][Full Text] [Related]
34. [Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients]. Zeng AZ; Deng H; Peng FY; Xin XJ; Yang C; Li QL; Guo JJ; Zhang ZZ; Hao MJ; Yuan Z; Huang WX; Huang AL Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):412-5. PubMed ID: 18578989 [TBL] [Abstract][Full Text] [Related]
35. [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. Xu Z; Chen LB; Cao H; Shu X; Xu QH; Li G; Xie QF Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):224-6. PubMed ID: 21186534 [TBL] [Abstract][Full Text] [Related]
36. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670 [TBL] [Abstract][Full Text] [Related]
37. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
38. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]. Yang Q; Gong ZJ; Hu DF Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686 [TBL] [Abstract][Full Text] [Related]
39. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL; N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916 [TBL] [Abstract][Full Text] [Related]
40. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine. Zhou C; Peng G; Jin X; Tang J; Chen Z Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]